In-depth structure-function profiling of the complex formation between clotting factor VIII and heme

• Published in: Thrombosis research 2024-05, Vol.237, p.184-195
• Main Authors: Hopp, Marie-T., Ugurlar, Deniz, Pezeshkpoor, Behnaz, Biswas, Arijit, Ramoji, Anuradha, Neugebauer, Ute, Oldenburg, Johannes, Imhof, Diana
• Format: Article
• Language: English
• Subjects: Coagulation factor VIII; Heme; Hemolysis; Hemophilia A; Hemorrhage
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/j.thromres.2024.04.006

Blood disorders, such as sickle cell disease, and other clinical conditions are often accompanied by intravascular hemolytic events along with the development of severe coagulopathies. Hemolysis, in turn, leads to the accumulation of Fe(II/III)-protoporphyrin IX (heme) in the intravascular compartment, which can trigger a variety of proinflammatory and prothrombotic reactions. As such, heme binding to the blood coagulation proteins factor VIII (FVIII), fibrinogen, and activated protein C with functional consequences has been demonstrated earlier. We herein present an in-depth characterization of the FVIII-heme interaction at the molecular level and its (patho-)physiological relevance through the application of biochemical, biophysical, structural biology, bioinformatic, and diagnostic tools. FVIII has a great heme-binding capacity with seven heme molecules associating with the protein. The respective binding sites were identified by investigating heme binding to FVIII-derived peptides in combination with molecular docking and dynamic simulation studies of the complex as well as cryo-electron microscopy, revealing three high-affinity and four moderate heme-binding motifs (HBMs). Furthermore, the relevance of the FVIII-heme complex formation was characterized in physiologically relevant assay systems, revealing a ~ 50 % inhibition of the FVIII cofactor activity even in the protein-rich environment of blood plasma. Our study provides not only novel molecular insights into the FVIII-heme interaction and its physiological relevance, but also strongly suggests the reduction of the intrinsic pathway and the accentuation of the final clotting step (by, for example, fibrinogen crosslinking) in hemolytic conditions as well as a future perspective in the context of FVIII substitution therapy of hemorrhagic events in hemophilia A patients. [Display omitted] •Coagulation factor VIII (FVIII) binds rapidly up to seven heme molecules.•Heme binds to sequence stretches of functional relevance for FVIII.•Labile heme causes distinct structural changes in FVIII, including increased flexibility.•FVIII cofactor function is significantly impaired by heme in blood plasma.